A bispecific antibody targeting CLDN18.2 and 4-1BB induces potent anti-tumor efficacy with an extraordinary safety profile

被引：0

作者：

Chen, Junying ^{[1
]}

Huang, Weifeng ^{[2
]}

Liang, Zhiquan ^{[1
]}

Miao, Xiaoniu ^{[1
]}

Peng, Shaogang ^{[2
]}

Wang, Chao ^{[1
]}

Dong, Tiantian ^{[1
]}

Tsun, Andy ^{[1
]}

Luo, Yi ^{[1
]}

机构：

[1] Biotheus Inc, Zhuhai, Peoples R China

[2] Biotheus Suzhou Co Ltd, Suzhou, Peoples R China

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5555

引用

页数：2

共 50 条

[41] First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
Ku, G.
Shen, L.
Klempner, S. J.
Pan, H.
Kratz, J.
Liang, X.
Deng, Y.
Kim, S.
Wang, Z.
Feller, L.
Powderly, J.
Dayyani, F.
Schneider, R. E.
Girda, E.
Berlin, J. D.
Spencer, K.
Nguyen, M. T.
Wang, V.
Xu, C.
Zhu, A.
ANNALS OF ONCOLOGY, 2023, 34 : S631 - S631
[42] POTENT TUMOR-DIRECTED T CELL ACTIVATION AND IN VIVO TUMOR INHIBITION INDUCED BY A 4-1BB X 5T4 ADAPTIR™ BISPECIFIC ANTIBODY
Nelson, Michelle
Miller, Robert
Nilsson, Anneli
Ljung, Lill
Chunyk, Allison
McMahan, Catherine
Bienvenue, David
Askmyr, Maria
Hernandez-Hoyos, Gabriela
Fritzell, Sara
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A507 - A507
[43] 4-1BB ligation following peptide immunization amplifies an anti-tumor CTL response
Wilcox, RA
Tamada, K
Chapoval, AI
Sica, G
Flies, D
Johnson, A
Pease, LR
Chen, L
FASEB JOURNAL, 2000, 14 (06): : A1004 - A1004
[44] 4-1BB Transduced Human T Cells Demonstrate an Improved Anti-Tumor Activity
Daniel-Meshulam, I.
Cohen, C. J.
HUMAN GENE THERAPY, 2009, 20 (05) : 542 - 542
[45] ABL503 (TJ-L14B), PD-L1X4-1BB BISPECIFIC ANTIBODY INDUCES SUPERIOR ANTI-TUMOR ACTIVITY BY PD-L1-DEPENDENT 4-1BB ACTIVATION WITH THE INCREASE OF 4-1BB+CD8+T CELLS IN TUMOR MICROENVIRONMENT
Jung, Uijung
Jeon, Jaehyoung
Lee, Shinai
Jin, Hyung-Seung
Kim, Youngkwang
Sung, Eunsil
Kim, Hyunjoo
Lim, Yangmi
Won, Jonghwa
Wang, Zhengyi
Jiang, Wenqing
Jung, Jaeho
You, Gihoon
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A935 - A935
[46] The anti-tumor effects of an adenoviral vaccine expressing 4-1BB ligand in a murine melanoma model
Ragonnaud, E.
Andersson, A.
Jensen, B. A. H.
Thomsen, A. R.
Holst, P. J.
IMMUNOLOGY, 2012, 137 : 723 - 723
[47] A novel 4-1BB/HER2 bispecific antibody shows potent antitumor activities by increasing and activating tumor-infiltrating T cells
Shen, Aolin
Liu, Wenting
Wang, Huizhen
Zeng, Xiaoli
Wang, Mengli
Zhang, Dayan
Zhao, Qun
Fang, Qing
Wang, Fengrong
Cheng, Liansheng
Shen, Guodong
Li, Yongxiang
AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (07): : 3246 - 3256
[48] Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
Liu, Guizhong
Luo, Peter
FRONTIERS IN IMMUNOLOGY, 2023, 14
[49] Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity
Hangiu, Oana
Compte, Marta
Dinesen, Anders
Navarro, Rocio
Tapia-Galisteo, Antonio
Mandrup, Ole A.
Erce-Llamazares, Ainhoa
Lazaro-Gorines, Rodrigo
Nehme-Alvarez, Daniel
Dominguez-Alonso, Carmen
Harwood, Seandean L.
Alfonso, Carlos
Blanco, Belen
Rubio-Perez, Laura
Jimenez-Reinoso, Anais
Diez-Alonso, Laura
Blanco, Francisco J.
Sanz, Laura
Howard, Kenneth A.
Alvarez-Vallina, Luis
ISCIENCE, 2022, 25 (09)
[50] A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody
Dai, Tongcheng
Sun, Hao
Liban, Tyler
Vicente-Suarez, Ildefonso
Zhang, Bin
Song, Yongping
Jiang, Zhongxing
Yu, Jifeng
Sheng, Jackie
Lv, Binhua
SCIENTIFIC REPORTS, 2024, 14 (01):

← 1 2 3 4 5 →